Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wearable Devices Ltd. (WLDS) SEC filings page on Stock Titan aggregates the company’s public reports as a foreign private issuer, giving investors structured access to its regulatory disclosures. Wearable Devices files primarily on Form 6-K under the Securities Exchange Act of 1934, and these reports often attach press releases or transaction documents that explain key corporate and financing events.
Recent 6-K filings describe registered direct offerings of ordinary shares and pre-funded warrants, concurrent private placements of ordinary warrants, and an at-the-market sales agreement for ordinary shares. These filings outline terms such as offering structures, use of registration statements on Form F-3, warrant exercise conditions, lock-up provisions and commission arrangements with placement agents or sales agents. Other 6-Ks cover matters like annual and special general meetings, amendments to the company’s compensation policy, and increases in authorized share capital through changes to its articles of association.
For those analyzing WLDS, the filings also reference clinical and technology milestones when they are furnished as exhibits, such as the neurorehabilitation pilot with Soroka University Medical Center and grant support from the Israel Innovation Authority. While detailed financial statements are not included in the excerpts provided here, the 6-K framework allows the company to incorporate press releases and legal opinions by reference into existing registration statements on Form F-3 and Form S-8.
On Stock Titan, users can review these WLDS filings in chronological order and use AI-powered summaries to interpret complex legal and transactional language. The platform highlights essential elements of each report—such as the nature of an offering, key conditions, and referenced exhibits—so readers can more quickly understand how each filing relates to Wearable Devices’ capital structure, governance decisions and product-related disclosures.
Wearable Devices Ltd. is carrying out a 1‑for‑3 reverse share split of its ordinary shares and publicly traded warrants. Every three existing shares or warrants will be consolidated into one, with warrant exercise prices adjusted proportionally.
The move aims to increase the share price to help regain compliance with Nasdaq’s $1.00 minimum bid requirement and protect the company’s continued listing on the Nasdaq Capital Market. After the split, issued and outstanding ordinary shares will be reduced from 10,593,227 to approximately 3,531,076, and publicly held warrants from 98,589 to approximately 32,863, while authorized capital remains at 500,000,000 shares.
The split, approved by shareholders and the board at a 1‑for‑3 ratio, will take effect for trading on a split‑adjusted basis when the market opens on March 11, 2026. Fractional positions will be rounded to the nearest whole share or warrant, and outstanding equity awards and plan reserves will be adjusted proportionally.
Wearable Devices Ltd. reported that its Board of Directors approved an increase in the number of ordinary shares reserved for its 2024 Global Equity Incentive Plan. The reserve rose by 1,431,713 shares, from 2,473,856 to 3,905,569 ordinary shares.
This change expands the pool of shares available for future equity-based awards to employees, directors, and other eligible participants under the plan. The report is also incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.
Wearable Devices Ltd. registers for the resale by a selling shareholder of up to 7,043,500 Ordinary Shares, consisting of 1,230,000 shares issuable upon exercise of October Warrants and 5,813,500 shares issuable upon exercise of November Warrants, pursuant to a Form F-1 prospectus dated
The company will not receive proceeds from shares sold by the selling shareholder; the company would receive up to
Wearable Devices Ltd. held a special shareholder meeting where a quorum was reached after an adjournment and all seven proposals were approved. A key outcome was adoption of an amended and restated compensation policy for executives and directors.
The updated policy increases the chief executive officer’s maximum base salary and raises annual bonus caps. It also revises the mix between fixed and variable pay by role, expands equity-based compensation limits for office holders, and increases the maximum annual equity grants for directors. The detailed policy, dated September 2025, is attached as an exhibit and will govern salaries, bonuses, equity awards, change-of-control treatment and clawback mechanisms for the company’s office holders.
Wearable Devices Ltd. Schedule 13G shows Armistice Capital, LLC and Steven Boyd jointly report beneficial ownership of 619,818 ordinary shares, representing 9.99% of the class as of 12/31/2025. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager and exercises voting and dispositive power under an Investment Management Agreement; the Master Fund disclaims beneficial ownership due to its inability to vote or dispose of the securities under that agreement. The joint filing is signed by Steven Boyd and dated 02/17/2026.
Wearable Devices Ltd. filed a Form 6-K highlighting a strategic product initiative and leadership appointment. The company plans to launch the Mudra Experience Studio, a developer platform that turns its neural input technology into a universal gesture language for extended reality (XR), mobile, desktop, and AI-powered applications.
The platform will offer production-ready SDKs, standardized gesture taxonomy, and integration with AI-driven development tools, aiming to let developers build once and deploy across Apple, Meta, Android XR, and desktop ecosystems. Wearable Devices opened a priority waitlist to support a 2026 rollout and reports strong early developer interest.
The company also appointed Ron Kaldes as Head of Growth, AI & Innovation to help drive the ai6 Labs and Mudra Experience Studio strategy, leveraging his background in consumer technology and AI consulting. The filing incorporates parts of this press release into existing S-8 and F-3 registration statements.
Wearable Devices Ltd. has launched ai6 Labs, a neural AI ecosystem designed to bridge human intent with digital reality using non-invasive Electromyography and its Mudra technology. The platform links foundational research, product commercialization, and rapid AI experimentation into a closed-loop system intended to accelerate innovation in touchless, intent-driven human–machine interaction.
The company positions ai6 Labs as a three-pillar ecosystem that turns biological signals into digital commands in a faster and more scalable way. Management describes this as an inflection point for AI wearables, extended reality gesture control, and non-invasive brain–computer interfaces, supporting its broader neural input product strategy.
Wearable Devices Ltd. appointed Kobbi Nir as an independent director to its Board of Directors. He is classified as a Class II director and is expected to be submitted for re-appointment at the company’s 2027 Annual General Meeting.
Mr. Nir will serve on the Board’s audit committee and compensation committee, bringing experience as CFO and deputy CEO of Moodify Ltd. and prior senior finance and board roles. He replaces Yaacov Goldman, who stepped down from the Board effective January 31, 2026, with the company stating his resignation was not due to any disagreement over operations, policies, or practices.